5
ALL5
AusperBioYear
5
ALL2
20243
2023DEALS // DEV.
5
ALL5
DevelopmentsCountry
5
ALL5
CHINA5
ALL5
Not ApplicableTherapeutic Area
5
ALL4
Infections and Infectious Diseases1
TechnologyStudy Phase
5
ALL1
Approved4
Phase IDeal Type
0
ALLProduct Type
5
ALL4
Large molecule1
PeptideDosage Form
4
ALL3
Injectable/Injection1
InjectionLead Product
5
ALL5
AHB-137Target
0
ALLLead Product(s) : AHB-137
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
AusperBio Receives Breakthrough Designation for AHB-137 in Chronic Hepatitis B
Details : AHB-137 is an unconjugated antisense oligonucleotide targeting all HBV RNA, which is being developed for the treatment of patients with chronic hepatitis B.
Brand Name : AHB-137
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 10, 2024
Lead Product(s) : AHB-137
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AHB-137
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
AusperBio Announces Major Progress in AHB-137 Clinical Development
Details : AHB-137 is an unconjugated antisense oligonucleotide targeting all HBV RNA, which is being developed for the treatment of patients with chronic hepatitis B.
Brand Name : AHB-137
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 14, 2024
Lead Product(s) : AHB-137
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AHB-137
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
AusperBio Announces FDA Clearance of IND Application of AHB-137 in Chronic Hepatitis B Treatment
Details : AHB-137 is an unconjugated antisense oligonucleotide, which is received FDA Clearance of IND Application of AHB-137 in Chronic Hepatitis B Treatment. he clinical trial in the US is part of a multiregional, randomized, double-blinded, placebo-controlled s...
Brand Name : AHB-137
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 25, 2023
Lead Product(s) : AHB-137
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AHB-137
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
AusperBio Announces IND Approval from China CDE for HBV ASO AHB-137
Details : AHB-137 is an unconjugated antisense oligonucleotide (ASO) with the potential treatment to be a backbone for the functional cure of Chronic Hepatitis B.
Brand Name : AHB-137
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 28, 2023
Lead Product(s) : AHB-137
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AHB-137
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AHB-137 is a potential best-in-class, highly potent, pan-genotypic antisense oligonucleotide (ASO) targeting all HBV RNA for the treatment of CHB patients. AHB-137 has shown best-in-class activity in reducing HBsAg across multiple preclinical models.
Brand Name : AHB-137
Molecule Type : Peptide
Upfront Cash : Not Applicable
March 09, 2023
Lead Product(s) : AHB-137
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?